TransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating restated by stock analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports.

A number of other analysts also recently issued reports on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Piper Sandler reissued an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, TransMedics Group currently has an average rating of "Moderate Buy" and an average price target of $128.70.

TransMedics Group Stock Performance

TMDX traded up $3.46 on Tuesday, reaching $139.05. The company had a trading volume of 783,703 shares, compared to its average volume of 1,360,053. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market cap of $4.70 billion, a P/E ratio of 147.93 and a beta of 2.10. The company's fifty day moving average is $101.54 and its 200 day moving average is $80.26. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same quarter in the prior year, the business earned $0.35 EPS. TransMedics Group's quarterly revenue was up 48.2% on a year-over-year basis. As a group, analysts predict that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the sale, the director now owns 732 shares of the company's stock, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David Weill sold 732 shares of the company's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director now directly owns 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,732 shares of company stock valued at $1,416,710. Company insiders own 7.00% of the company's stock.

Institutional Trading of TransMedics Group

A number of institutional investors and hedge funds have recently made changes to their positions in TMDX. Janney Montgomery Scott LLC bought a new stake in shares of TransMedics Group during the 4th quarter worth approximately $239,000. CENTRAL TRUST Co lifted its stake in TransMedics Group by 162.2% in the 4th quarter. CENTRAL TRUST Co now owns 1,442 shares of the company's stock valued at $90,000 after purchasing an additional 892 shares during the last quarter. Jennison Associates LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $555,000. Tempus Wealth Planning LLC bought a new position in TransMedics Group in the 4th quarter valued at approximately $346,000. Finally, Guidance Capital Inc. lifted its stake in TransMedics Group by 54.5% in the 4th quarter. Guidance Capital Inc. now owns 3,642 shares of the company's stock valued at $222,000 after purchasing an additional 1,284 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.